Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • Nov 19, 2013

166_ip_2013-11-19_b1c04f11-4188-4ecf-9eae-3f5ea9b82a07.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

A Leading Global Health Care Group

MainFirst German & Swiss Conference, November 19, 2013

For detailed financial information please see our annual/quarterly reports and/or conference call materials on our website.

Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Fresenius At a Glance

A Global Leader in Health Care Products and Services

  • Sales >€20 bn, net income >€1 bn in 2013e
  • Strong and well-diversified portfolio
  • Global presence in approx. 100 countries
  • Long-term opportunities in growing markets

Attractive total shareholder return: 10-year annual average of 24%

Strong and Balanced Health Care Portfolio

Dialysis products and services

Ownership: 31% Ownership: 100% Ownership: 100% Ownership: 77%

Hospital supply Hospital operations Hospital projects and services

i
b
i
2
0
1
2
G
N
I
C
t
t
t
r
o
u
p
e
n
c
o
m
e
o
n
r
u
o
n
2
9
%		 4
7
%		 2
2
%		 3
%

Corporate: -1%

Fresenius Group: Financial Results

l
S
a
e
s		 1
E
B
I
T		 1
i
N
t
e
n
c
o
m
e
/
Q
3
3
1
1
-		 €
0
3
2
1
5
m
,		 €
2
2
0
2
m
,		 €
3
7
5
m
h
G
t
t
t
t
o
a
c
o
n
s
a
n
r
w
t
c
e
n
c
a
e
s
u
r
r
y
r		 9
%		 %
1		 2
%
1
h
l
G
t
t
t
r
o
w
a
a
c
u
a
t
c
u
r
r
e
n
c
y
r
a
e
s		 %
7		 %
1
-		 0
%
1

1Before one-time items

Fresenius Group: Financial Results by Business Segment

/
Q
1
3
1
3
-		 i
F
r
e
s
e
n
u
s
d
i
l
M
C
e
c
a
a
r
e		 i
F
r
e
s
e
n
u
s
b
i
K
a		 i
F
r
e
s
e
n
u
s
l
i
H
e
o
s		 i
F
r
e
s
e
n
u
s
d
V
a
m
e
S
l
a
e
s
G
h
t
o
r
w		 \$
U
S
1
0
7
4
3
m
,
6
%		 €
3
2
7
4
m
,
%
1
1		 €
2
3
5
7
m
,
8
%		 €
6
5
4
m
2
2
%
E
B
I
T
h
G
t
o
r
w		 \$
U
S
1
5
9
5
m
,
4
%
-		 €
6
9
5
m
%
1
-		 €
2
8
2
m
2
2
%		 €
2
5
m
%
4

Q3 Business Update

Operations & Markets

North America

  • 8% organic sales growth in Q3 exceeding expectations
  • Propofol: Maintained 88% IMS market share in September; October shipments >45% over September volumes following de-stocking by U.S. hospitals in August/September

China

    • 6% volume growth in Q3; ongoing probes at other drug makers tightened market access
  • -2% organic sales decline in Q3 reflecting price cuts
    • Underlying growth drivers intact – government plans to triple health care sector spending by 2020

Asia-Pacific excluding China

-13% organic sales growth in Q3

Q3 Business Update

Operations & Markets

b
l
d
l
l
d
S
H
E
t
t
o
o
o
m
e
e
p
a
c
e
m
e
n
p
o
c
s
v
u
r
r
u
l
b
l
d
E
M
A
i
i
H
E
S
i
i
i
i
i
t
t
t
t
t
p
o
s
o
n
e
m
a
n
s
a
a
a
e
n
e
s
e
p
a
e
n
r
v
r
r
c
–
-
l
f
l
d
b
d
i
i
i
i
E
C
i
i
t
t
p
o
p
a
o
n
s
n
a
e
c
s
o
n
o
p
e
a
n
o
m
m
s
s
o
n
e
p
e
c
e
u
;
y
u
r
x
s
o
o
n
l
d
b
l
3
0
%
i
i
Q
3,
2
0
%
Y
T
D
i
i
i
t
t
t
s
a
e
s
e
c
o
n
n
s
a
a
o
n
r
u
z
~
~
-
,
d
i
2
0
1
4
t
e
p
e
c
e
n
x
b
l
b
2
0
F
i
i
i
1
4
t
t
a
v
o
r
a
e
r
e
m
u
r
s
e
m
e
n
e
n
v
r
o
n
m
e
n
n
2
0
1
G
-i
f
l
2.
8
1
%
4
D
R
t
n
a
o
r
-
h
d
f
h
H
i
i
i
i
i
D
R
G
i
2
0
0
3
t
t
t
t
t
g
e
s
n
c
r
e
a
s
e
s
n
c
e
n
r
o
u
c
o
n
o
e
s
y
s
e
m
n
-
(
)
2
0
1
3
2.
0
%
:

Q3 Business Update

Strategic Initiatives

Acquisition of 43 hospitals from Rhön-Klinikum AG Vast majority of transaction expected to close by end of 2013 Emerging markets expansion Indonesia joint venture – creates market leader in I.V. generics, attractive platform for future Kabi product rollout Promising acquisition pipeline to expand presence in fastgrowing markets HELIOS hospital Rhön hospital

Fresenius Group: Financial Outlook by Business Segment Fully Confirmed

i
P
e
o
s
r
v
u		 N
e
w
i
F
e
e
r
s
n
u
s
b
i
K
a		 l
h
S
t
a
e
s
g
o
r
w
c
c
S
l
h
t
i
e
g
o
a
s
r
w
o
r
g
a
n
c
E
B
I
T
i
l.
l
F
m
a
r
g
n
e
c
e
n
a
x
w
i
E
B
I
T
l.
l
i
F
m
a
r
g
n
n
c
e
n
w
a		 1
2
%
1
4
%
–
3
%
5
%
–
1
9
%
2
0
%
–
8
%
9
%
1
1
–
i
F
r
e
s
e
n
u
s
l
i
H
e
o
s		 l
h
S
t
i
a
e
s
g
r
o
w
o
g
a
n
c
r
E
B
I
T		 3
%
5
%
–
€
3
7
0
€
3
9
5
m
–		 h
l
f
f
p
p
e
a
o
a
n
g
e
u
r
r
i
F
r
e
s
e
n
u
s
d
V
a
m
e		 l
h
S
t
a
e
s
g
r
o
w
h
E
B
I
T
t
g
o
r
w		 8
2
%
1
%
–
5
%
1
0
%
–		 d
f
u
p
p
e
r
e
n
o
r
a
n
g
e

2013 Fresenius Kabi EBIT guidance excluding Fenwal integration costs (~€50 million).

Fresenius Group: Outlook Fully Confirmed

h
R
t
e
e
n
e
g
o
v
u
r
w
t
t
t
a
c
o
n
s
a
n
c
e
n
c
u
r
r
y		 %
0
%
7
1
‒
1
h
N
i
t
t
e
n
c
o
m
e
g
o
r
w
t
t
t
a
c
o
n
s
a
n
c
e
n
c
u
r
r
y		 1
1
%
1
4
%
‒

1 Net income attributable to shareholders of Fresenius SE& Co.KGaA; 2013 adjusted for Fenwal integration costs (~€50 million pre-tax); 2012 adjusted for a non-taxable investment gain of €34 million and other one-time costs of €17 million at Fresenius Medical Care and for one-time costs of €29 million related to the offer to RHÖN-KLINIKUM AG shareholders.

Attachments

Fresenius Group: Profit and Loss Statement

€
m		 /
/
Q
3
1
3
Q
1
3
1
3
-		 h
G
Q
t
r
o
w		 /
3
1
3
Y
Y
o
l
t
a
c
a
u
t
a
e
s
r		 t
t
c
o
n
s
a
n
t
a
e
s
r
S
l
e
a
s		 0
5
4
5
,		 0
3
2
1
5
,		 %
4		 9
%
1
E
B
I
T		 7
5
4		 2
2
0
2
,		 4
%
-		 0
%
N
i
t
t
t
e
n
e
e
s
r		 3
6
1
-		 9
4
4
-		 9
%
1		 %
1
4
I
t
n
c
o
m
e
a
x
e
s		 1
7
3
-		 4
9
6
-		 3
%		 3
%
-
2
N
i
t
e
n
c
o
m
e		 2
7
1		 3
7
5		 9
%		 2
%
1

1 2013 adjusted for Fenwal integration costs (Q3: €7 million; Q1-3: €34 million)

Net income attributable to shareholders of Fresenius SE & Co. KGaA, 2013 adjusted for Fenwal integration costs (Q3: €6 million; Q1-3: €26 million), 2012 adjusted for investment gain of €34 million at Fresenius Medical Care and for one-time costs related to the offer to RHÖN-KLINIKUM AG shareholders (Q3: €5 million; Q1-3: €31 million).

Cash Flow Development LTM

€
m		 i
O
C
F
t
p
e
r
a
n
g		 C
a
e
p
x		 (
)
t
e
n		 C
F
e
e
a
r
s		 1
h
l
F
o
w
Q
3
/
3
L
T
M
1-
1		 i
L
T
M
M
a
g
n
r		 Q
3
/
3
L
T
M
1-
1		 i
L
T
M
M
a
g
n
r		 Q
3
/
3
L
T
M
1-
1		 i
L
T
M
M
a
g
n
r
4
4
7		 9
%
1		 2
9
8
-		 6
%
1
-		 9
1
4		 3
0
%
2
6
9		 7
9
%		 1
7
4
-		 5
1
%
-		 9
5		 3
2
8
%
6
4
-		 8
%
4
-		 1
3
-		 1
3
%
-		 9
5
-		 6
1
%
-
Co
/
te
rp
or
a
he
O
t
r		 1
2
-		 /
n
a		 1
2
-		 /
n
a		 2
4
-		 /
n
a
l.
C
F
M
ex
c		 6
8
5		 2
9
%
7		 9
4
7
-		 %
5
4
-		 6
1
1		 2
2
%
5
G
ro
up		 2
1
9
7
,		 1
0
9
%		 1
0
4
7
-
,		 5
2
%
-		 1
1
5
0
,		 5
7
%

1 Before Acquisitions and Dividends

2 Incl. FMC dividend

3 Understated: 3.8% excluding €34 million of capex commitments from acquisitions

Margin = in % of sales

Fresenius Group: Debt and Interest Ratios

1Pro forma Fenwal

  • 2 Adjusted for one-time costs (-€1 million) related to the offer to the shareholders of RHÖN-KLINIKUM AG, for other one-time costs (€86 million) at Fresenius Medical Care as well as one-time integration costs (€34 million) at Fenwal
  • 3Pro forma including Liberty Dialysis Holdings, Inc., Damp Group, and Fenwal

4Adjusted for one-time costs (€6 million) related to the offer to the shareholders of RHÖN-KLINIKUM AG and for other one-time costs (€86 million) at Fresenius Medical Care.

Fresenius Kabi: Organic Sales Growth at Upper End of Guidance

€
m		 /
Q
1
3
1
3
-		 /
Q
1
3
1
2
-		 i
O
r
g
a
n
c
h
G
t
o
r
w
E
u
r
o
p
e		 1
5
2
4
,		 1
4
4
9
,		 2
%
h
N
A
i
t
o
m
e
r
r
c
a		 8
1
1
5
,		 9
0
1		 %
7
f
i
i
i
A
P
s
a
a
c
c
-		 6
8
9		 6
2
4		 6
%
/
f
L
i
A
i
A
i
t
a
n
m
e
r
c
a
r
c
a		 3
7
1		 3
6
2		 8
%
l
l
T
t
o
a
s
a
e
s		 3
2
7
4
,		 3
3
6
3
,		 %
5

Fresenius Kabi: Organic Sales Growth at Upper End of Guidance

€
m		 /
Q
1
3
1
3
-		 /
Q
1
3
1
2
-		 i
O
r
g
a
n
c
h
G
t
r
o
w
f
h
I
i
T
n
u
s
o
n
e
r
a
p
y		 7
4
1		 7
5
4		 3
%
I.
V
D
r
u
g
s		 3
0
8
1
,		 2
3
1
7
,		 6
%
C
l
l
i
i
N
i
i
t
t
n
c
a
o
n
u
r		 9
9
5		 9
8
4		 %
4
d
l
/
M
i
D
i
e
c
a
e
c
e
s
v
f
h
l
i
T
T
a
n
s
s
o
n
e
c
n
o
o
g
r
u
y		 6
9
8		 3
2
5		 %
5
l
l
T
t
o
a
s
a
e
s		 3
7
4
2
,		 3
3
6
3
,		 5
%

Fresenius Kabi: EBIT Margin Fully in Line with Guidance

€
m		 Q
3
/
3
1
1
-		 Q
3
/
2
1
1
-		 G
h
t
o
r
w
E
o
p
e
u
r
M
i
a
g
n
r		 2
5
5
1
6.
7
%		 2
8
4
1
9
6
%		 1
0
%
-
h
N
A
i
t
o
r
m
e
r
c
a
M
i
a
g
n
r		 4
3
0
3
7.
1
%		 3
7
7
4
1.
4
%		 1
4
%
f
/
/
f
i
i
i
i
i
i
A
P
L
t
A
A
s
a
a
c
c
a
n
m
e
c
a
c
a
r
r
-
M
i
a
r
g
n		 1
8
0
1
7.
0
%		 2
1
3
2
1.
2
%		 1
%
5
-
C
d
C
&
R
D
t
t
o
r
p
o
r
a
e
a
n
o
r
p
o
r
a
e		 0
1
7
-		 1
7
4
-		 2
%
l
(
i
l.
l
)
T
E
B
I
T
F
t
o
a
e
a
n
c
n
w
i
M
a
r
g
n		 6
9
5
8
1
6
%		 0
0
7
8
2
0
%		 %
1
-
l
(
l.
l
)
T
E
B
I
T
F
t
o
a
e
c
e
n
a
x
w
i
M
a
r
g
n		 6
6
8
9
6
%
1		 0
0
7
2
0
8
%		 %
5
-

Q1-3/13 EBIT excluding Fenwal integration costs of €34 million.

Fresenius Helios: Excellent Sales and EBIT Growth

€
m		 /
Q
1
3
1
3
-		 /
Q
1
3
1
2
-		 h
G
t
r
o
w
l
l
T
t
o
a
s
a
e
s		 2
3
5
7
,		 2
3
4
7
,		 8
%
E
B
I
T
b
l
h
d
l
f
l
E
i
i
i
i
t
t
s
a
s
e
c
n
c
p
o
r
o
o
i
M
a
r
g
n		 2
9
7
1
1.
5
%		 2
3
4
1
0.
0
%		 9
%
1
/
A
i
i
i
D
i
i
t
t
t
c
q
u
s
o
n
s
v
e
s
u
r
e
s
(
l
d
/
d
l
d
)
i
t
i
i
t
i
1
<
c
o
n
s
o
a
o
n
e
c
o
n
s
o
a
o
n
y
r		 3 2
-
l
T
t
E
B
I
T
o
a		 2
8
2		 2
3
2		 2
2
%
i
M
a
r
g
n		 1
1.
1
%		 9
9
%

Fresenius Helios: Performance Indicators

/
Q
1
3
1
3
-		 /
Q
1
3
1
2
-		 h
C
a
n
g
e
1
f
h
l
N
i
t
o
o
o
s
p
a
s
l
A
t
i
i
c
u
e
c
a
r
e
c
n
c
s
-
l
P
i
i
t-
t
o
s
a
c
e
c
a
e
c
n
c
s
u
r
-		 7
4
5
1
2
3		 7
2
0
5
2
2		 3
%
2
%
5
%
1
f
b
d
N
o
o
e
s
l
A
t
i
i
c
u
e
c
a
r
e
c
n
c
s
-
l
P
t-
t
i
i
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 2
3
5
2
9
,
8,
9
2
1
1
6
4,
1
7		 2
3
2
8
6
,
8,
0
1
7
1
8
4,
5
5		 1
%
%
1
%
1
d
A
i
i
m
s
s
o
n
s
(
i
i
)
A
t
t
t
c
u
e
c
a
r
e
n
p
a
e
n
-		 6
8,
3
0
5
7		 3,
3
3
5
4
1		 %
5
O
c
c
u
p
a
n
c
y
P
t-
t
o
s
a
c
u
e
c
a
r
e
-		 8
4
%		 8
5
%
l
h
f
(
d
)
A
t
t
v
e
r
a
g
e
e
n
g
o
s
a
y
a
y
s
A
t
c
u
e
c
a
r
e
-
P
t-
t
o
s
a
c
u
e
c
a
r
e
-		 6.
6
2
6.
8		 6.
7
2
2
7.

1Dec 31, 2012

Fresenius Vamed: Excellent Sales Growth

€
m		 /
Q
1
3
1
3
-		 /
Q
1
3
1
2
-		 h
G
t
r
o
w
b
P
j
i
t
o
e
s
n
e
s
s
r
c
u		 3
3
2		 2
8
5		 1
6
%
b
S
i
i
e
c
e
s
n
e
s
s
r
v
u		 3
2
2		 2
5
1		 8
2
%
l
l
T
t
o
a
s
a
e
s		 6
5
4		 5
3
6		 2
2
%
l
T
E
B
I
T
t
o
a		 2
5		 2
4		 %
4
i
M
a
r
g
n		 3
8
%		 %
4
5
1
O
d
i
k
t
e
n
a
e
r
r		 3
8
0		 3
2
2		 8
%
1
1
O
d
b
k
l
e
a
c
o
g
r
r		 0
3
1
4
,		 2
9
8
7		 %
5

1Project business only

2December 31, 2012

Excellent Financial Performance Driven by Strong Organic Growth and Acquisitions

Consistent Cash Generation and Proven Track Record of Deleveraging

Attractive Long-term Shareholder Returns

0,07 0,41 0,45 0,49 0,57 0,66 0,70 0,75 0,86 0,95 1,10 '93 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12€CAGR 16%

20th Consecutive Dividend Increase

Dividend growth aligned with EPS growth (before one-time items)

0 4 8 12 16 20 24DAX30Freseniusshare24.02% p.a. 10.15% p.a. %

Fresenius Outperforms Index

Compounded annual total return Dec 31, 2002 − Dec 31, 2012

Source: Bloomberg; dividends reinvested

Share Information

Share key facts

Number of shares1 178,839,237 Ticker symbol FRE Bloomberg symbol FRE GR Reuters symbol FREG.de

WKN / ISIN 578560 / DE0005785604

ADR key facts

Ticker symbol FSNUY Exchange OTC-market Depositary bank Deutsche Bank

Ratio 8 ADRs = 1 ordinary share ADR CUSIP / ISIN 35804M105 / US35804M1053 Structure Sponsored Level I ADR

1As of September 30, 2013

Financial Calendar 2014

2
5
0
2
2
0
1
4		 l
R
F
i
Y
2
0
1
3
t
e
p
o
r
o
n
s
c
a
e
a
r
0
6
0
5
2
0
1
4		 t
R
1
Q
2
0
1
4
t
t
s
e
p
o
r
o
n
u
a
r
e
r
1
6
0
5
2
0
1
4		 l
l
k
f
/
A
G
M
i
F
M
i
t
t
n
n
u
a
e
n
e
r
a
e
e
n
g
r
a
n
u
r
a
n
,
8
0
5
0
2
0
1
4		 t
h
l
f
R
1
2
0
1
4
t
s
e
p
o
r
o
n
a
0
2
0
4
1
1
1
4		 d
t
3
2
0
R
1
1
4
t
t
s
r
e
p
o
r
o
n
q
u
a
r
e
r
–

Please note that these dates could be subject to modifications.

Contact

G
d
B
i
i
t
r
g
r
u
n		 S
l
S
&
C
G
V
P
I
R
i
F
i
E
K
A
t
t
n
v
e
s
o
r
e
a
o
n
s
r
e
s
e
n
u
s
o
a
l
h
T
e
e
p
o
n
e
:
l
i
e
-m
a
:		 9
6
1
2
6
0
8
2
8
4
7
4
5
+
-
d
f
B
i
i
G
@
i
t.
g
n
e
s
e
n
s
c
o
m
r
r
u
r
u

For further information and current news: http://www.fresenius.com

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.